^
Association details:
Biomarker:EGFR G719S
Cancer:Non Small Cell Lung Cancer
Drug:gefitinib (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
New
Title:

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Excerpt:
First-line gefitinib for patients with advanced non–small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with standard chemotherapy.
Secondary therapy:
bisphosphonate bound paclitaxel
DOI:
10.1056/NEJMoa0909530
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients

Excerpt:
...- Activating EGFR mutations (G719A/C/S; Exon 19 insertion/deletion; L858R; L861Q)...
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

Excerpt:
Of the 33 patients with tumors positive for mutant EGFR, 4 patients had disease progression within 2 months of gefitinib treatment. All these tumors were squamous cell carcinoma and the patterns of mutation were delA767_V769 (exon 20), A763V mutation (exon 20), L858R mutation (exon 21), and a double substitution mutation, G719S and L861Q, in exons 18 and 21.
DOI:
10.1158/1078-0432.CCR-04-1981
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants

Excerpt:
In different EGFR variant-expressing 32D cells, only cells harboring L858R, E746-A750 deletion, and G719S mutants were clearly more sensitive to gefitinib than wild-type EGFR-expressing cells. 
DOI:
10.1038/sj.onc.1209159